Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt/Epix MS-325 vascular MRI imaging agent nearing Phase II -- Epix offering prospectus.

Executive Summary

EPIX MEDICAL MS-325 VASCULAR IMAGING AGENT PHASE II TRIALS will test the agent's ability to enhance magnetic resonance imaging of arteries and veins as an alternative to X-ray angiography, Epix Medical said in a recent initial public offering prospectus. The company believes that MS-325 may have applications in diagnosis of coronary artery disease, peripheral vascular disease and thrombosis. Epix is developing MS-325 in collaboration with Mallinckrodt.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel